Pharmacokinetic Model-Informed Precision Dosing of Natalizumab in Multiple Sclerosis.

ABSTRACT: Intravenous natalizumab is an effective treatment for relapsing-remitting multiple sclerosis. However, the standard treatment interval of 4 weeks may be excessive for many patients. Personalized interval extension using therapeutic drug monitoring (TDM) can result in adequate drug exposure while reducing hospital visits and healthcare costs. Here, we investigate to which extent TDM-guided personalized dosing can benefit from model-informed precision dosing (MIPD). Individual posterior PK estimates were derived using patient weight and two trough concentrations at the standard dose interval by Bayesian estimation using a newly developed population PK model. MIPD was compared to a previously deployed TDM-guided stratified personalized dosing protocol (SPD) using a decision tree to personaliz

SUBMITTER: van den Berg SPH 

PROVIDER: S-EPMC12167911 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature